304 related articles for article (PubMed ID: 27960087)
21. Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
Kung HN; Weng TY; Liu YL; Lu KS; Chau YP
PLoS One; 2014; 9(2):e88122. PubMed ID: 24505400
[TBL] [Abstract][Full Text] [Related]
22. X-ray repair cross-complementing protein 1 (XRCC1) loss promotes β-lapachone -induced apoptosis in pancreatic cancer cells.
Zheng Y; Zhang H; Guo Y; Chen Y; Chen H; Liu Y
BMC Cancer; 2021 Nov; 21(1):1234. PubMed ID: 34789190
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
Wu X; Li X; Li Z; Yu Y; You Q; Zhang X
J Med Chem; 2018 Dec; 61(24):11280-11297. PubMed ID: 30508483
[TBL] [Abstract][Full Text] [Related]
24. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
[TBL] [Abstract][Full Text] [Related]
25. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
[TBL] [Abstract][Full Text] [Related]
26. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone.
Bentle MS; Reinicke KE; Dong Y; Bey EA; Boothman DA
Cancer Res; 2007 Jul; 67(14):6936-45. PubMed ID: 17638905
[TBL] [Abstract][Full Text] [Related]
27. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
28. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE
Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448
[TBL] [Abstract][Full Text] [Related]
29. Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation.
Breton CS; Aubry D; Ginet V; Puyal J; Heulot M; Widmann C; Duchosal MA; Nahimana A
Biochimie; 2015 Sep; 116():141-53. PubMed ID: 26188110
[TBL] [Abstract][Full Text] [Related]
30. Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer.
Dou L; Liu H; Wang K; Liu J; Liu L; Ye J; Wang R; Deng H; Qian F
J Control Release; 2022 Sep; 349():876-889. PubMed ID: 35907592
[TBL] [Abstract][Full Text] [Related]
31. Synergistic Effect of β-Lapachone and Aminooxyacetic Acid on Central Metabolism in Breast Cancer.
Chang MC; Mahar R; McLeod MA; Giacalone AG; Huang X; Boothman DA; Merritt ME
Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893874
[TBL] [Abstract][Full Text] [Related]
32. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
[TBL] [Abstract][Full Text] [Related]
33. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone.
Chakrabarti G; Moore ZR; Luo X; Ilcheva M; Ali A; Padanad M; Zhou Y; Xie Y; Burma S; Scaglioni PP; Cantley LC; DeBerardinis RJ; Kimmelman AC; Lyssiotis CA; Boothman DA
Cancer Metab; 2015; 3():12. PubMed ID: 26462257
[TBL] [Abstract][Full Text] [Related]
34. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
35. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of poly(ADP-ribose) polymerase activation attenuates beta-lapachone-induced necrotic cell death in human osteosarcoma cells.
Liu TJ; Lin SY; Chau YP
Toxicol Appl Pharmacol; 2002 Jul; 182(2):116-25. PubMed ID: 12140175
[TBL] [Abstract][Full Text] [Related]
37. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
39. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H
Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
